Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors.

Published

Journal Article

BACKGROUND:Many epithelial ovarian cancer (EOC) risk factors relate to hormone exposure and elevated estrogen levels are associated with obesity in postmenopausal women. Therefore, we hypothesized that gene-environment interactions related to hormone-related risk factors could differ between obese and non-obese women. METHODS:We considered interactions between 11,441 SNPs within 80 candidate genes related to hormone biosynthesis and metabolism and insulin-like growth factors with six hormone-related factors (oral contraceptive use, parity, endometriosis, tubal ligation, hormone replacement therapy, and estrogen use) and assessed whether these interactions differed between obese and non-obese women. Interactions were assessed using logistic regression models and data from 14 case-control studies (6,247 cases; 10,379 controls). Histotype-specific analyses were also completed. RESULTS:SNPs in the following candidate genes showed notable interaction: IGF1R (rs41497346, estrogen plus progesterone hormone therapy, histology = all, P = 4.9 × 10(-6)) and ESR1 (rs12661437, endometriosis, histology = all, P = 1.5 × 10(-5)). The most notable obesity-gene-hormone risk factor interaction was within INSR (rs113759408, parity, histology = endometrioid, P = 8.8 × 10(-6)). CONCLUSIONS:We have demonstrated the feasibility of assessing multifactor interactions in large genetic epidemiology studies. Follow-up studies are necessary to assess the robustness of our findings for ESR1, CYP11A1, IGF1R, CYP11B1, INSR, and IGFBP2 Future work is needed to develop powerful statistical methods able to detect these complex interactions. IMPACT:Assessment of multifactor interaction is feasible, and, here, suggests that the relationship between genetic variants within candidate genes and hormone-related risk factors may vary EOC susceptibility. Cancer Epidemiol Biomarkers Prev; 25(5); 780-90. ©2016 AACR.

Full Text

Duke Authors

Cited Authors

  • Usset, JL; Raghavan, R; Tyrer, JP; McGuire, V; Sieh, W; Webb, P; Chang-Claude, J; Rudolph, A; Anton-Culver, H; Berchuck, A; Brinton, L; Cunningham, JM; DeFazio, A; Doherty, JA; Edwards, RP; Gayther, SA; Gentry-Maharaj, A; Goodman, MT; Høgdall, E; Jensen, A; Johnatty, SE; Kiemeney, LA; Kjaer, SK; Larson, MC; Lurie, G; Massuger, L; Menon, U; Modugno, F; Moysich, KB; Ness, RB; Pike, MC; Ramus, SJ; Rossing, MA; Rothstein, J; Song, H; Thompson, PJ; van den Berg, DJ; Vierkant, RA; Wang-Gohrke, S; Wentzensen, N; Whittemore, AS; Wilkens, LR; Wu, AH; Yang, H; Pearce, CL; Schildkraut, JM; Pharoah, P; Goode, EL; Fridley, BL; Ovarian Cancer Association Consortium and the Australian Cancer Study,

Published Date

  • May 2016

Published In

Volume / Issue

  • 25 / 5

Start / End Page

  • 780 - 790

PubMed ID

  • 26976855

Pubmed Central ID

  • 26976855

Electronic International Standard Serial Number (EISSN)

  • 1538-7755

International Standard Serial Number (ISSN)

  • 1055-9965

Digital Object Identifier (DOI)

  • 10.1158/1055-9965.EPI-15-1039

Language

  • eng